PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Acorda Therapeutics, Inc. (ACOR)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00484M6012
CUSIP00484M601
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$15.03M
EPS$2.61
PE Ratio4.64
PEG Ratio0.51
Revenue (TTM)$111.12M
Gross Profit (TTM)$82.43M
EBITDA (TTM)$11.51M
Year Range$8.98 - $24.20
Target Price$10.00
Short %0.90%
Short Ratio5.15

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds to compare with ACOR

Acorda Therapeutics, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Acorda Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%0.00%100.00%200.00%300.00%OctoberNovemberDecember2024FebruaryMarch
-98.36%
314.71%
ACOR (Acorda Therapeutics, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Acorda Therapeutics, Inc. had a return of -12.45% year-to-date (YTD) and 10.09% in the last 12 months. Over the past 10 years, Acorda Therapeutics, Inc. had an annualized return of -44.29%, while the S&P 500 had an annualized return of 10.89%, indicating that Acorda Therapeutics, Inc. did not perform as well as the benchmark.


PeriodReturnBenchmark
Year-To-Date-12.45%10.16%
1 month-1.41%3.47%
6 months-9.02%22.20%
1 year10.09%30.45%
5 years (annualized)-61.72%13.16%
10 years (annualized)-44.29%10.89%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
20246.16%-15.11%
2023-19.16%20.84%-36.02%2.19%53.98%

Risk-Adjusted Performance

Risk-Adjusted Performance Indicators

This table presents risk-adjusted performance metrics for Acorda Therapeutics, Inc. (ACOR) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratioSortino ratioOmega ratioCalmar ratioUlcer Index
ACOR
Acorda Therapeutics, Inc.
0.11
^GSPC
S&P 500
2.79

Sharpe Ratio

The current Acorda Therapeutics, Inc. Sharpe ratio is 0.11. A Sharpe ratio between 0 and 1.0 is considered sub-optimal.


Rolling 12-month Sharpe Ratio-0.500.000.501.001.502.002.503.00OctoberNovemberDecember2024FebruaryMarch
0.11
2.79
ACOR (Acorda Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Acorda Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%OctoberNovemberDecember2024FebruaryMarch
-99.75%
0
ACOR (Acorda Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Acorda Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Acorda Therapeutics, Inc. was 99.90%, occurring on Sep 29, 2022. The portfolio has not yet recovered.

The current Acorda Therapeutics, Inc. drawdown is 99.75%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.9%Jan 27, 20151934Sep 29, 2022
-66.96%Feb 13, 2006155Sep 22, 20061Sep 25, 2006156
-55.62%Jul 29, 200882Nov 20, 2008325Mar 11, 2010407
-52.87%May 4, 2010359Oct 3, 2011384Apr 16, 2013743
-37.5%May 8, 200789Sep 12, 200794Jan 28, 2008183

Volatility

Volatility Chart

The current Acorda Therapeutics, Inc. volatility is 22.83%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%5.00%10.00%15.00%20.00%25.00%30.00%OctoberNovemberDecember2024FebruaryMarch
22.83%
2.80%
ACOR (Acorda Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Acorda Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items